# Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

> **NCT02535221** · PHASE3 · RECRUITING · sponsor: **Peking University** · enrollment: 234 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Goserelin+TAM+AI
- **DRUG:** Epirubicin+CTX+5-Fu

## Key facts

- **NCT ID:** NCT02535221
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-07-29
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 234 (ESTIMATED)
- **Last updated:** 2021-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02535221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02535221, "Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02535221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*